136 related articles for article (PubMed ID: 19959583)
1. Amenorrhoea, menopause, and endocrine therapy for breast cancer.
Amir E; Seruga B; Freedman O; Clemons M
BMJ; 2009 Dec; 339():b4261. PubMed ID: 19959583
[No Abstract] [Full Text] [Related]
2. Urogenital disorders in women with adjuvant endocrine therapy after early breast cancer.
Baumgart J; Nilsson K; Stavreus-Evers A; Kask K; Villman K; Lindman H; Kallak T; Sundström-Poromaa I
Am J Obstet Gynecol; 2011 Jan; 204(1):26.e1-7. PubMed ID: 20950790
[TBL] [Abstract][Full Text] [Related]
3. Menopausal symptoms following tamoxifen treatment for breast cancer.
Barton DL
Oncology (Williston Park); 2008 Apr; 22(4 Suppl Nurse Ed):46-8. PubMed ID: 19856564
[TBL] [Abstract][Full Text] [Related]
4. Controversies in the management of patients with breast cancer: adjuvant endocrine therapy in premenopausal women.
Parton M; Smith IE
J Clin Oncol; 2008 Feb; 26(5):745-52. PubMed ID: 18258982
[No Abstract] [Full Text] [Related]
5. Side effects of aromatase inhibitors versus tamoxifen: the patients' perspective.
Garreau JR; Delamelena T; Walts D; Karamlou K; Johnson N
Am J Surg; 2006 Oct; 192(4):496-8. PubMed ID: 16978958
[TBL] [Abstract][Full Text] [Related]
6. Randomized, double-blind, placebo-controlled, crossover study of sertraline (Zoloft) for the treatment of hot flashes in women with early stage breast cancer taking tamoxifen.
Kimmick GG; Lovato J; McQuellon R; Robinson E; Muss HB
Breast J; 2006; 12(2):114-22. PubMed ID: 16509835
[TBL] [Abstract][Full Text] [Related]
7. The case of the harrowing hot flashes.
Eisenberg S
ONS Connect; 2012 Jun; 27(6):18. PubMed ID: 22774342
[No Abstract] [Full Text] [Related]
8. Toremifene and letrozole for advanced breast cancer.
Med Lett Drugs Ther; 1998 Apr; 40(1024):43-5. PubMed ID: 9580744
[No Abstract] [Full Text] [Related]
9. [Utility of neoadjuvant endocrine therapy for breast neoplasms].
Akashi-Tanaka S
Nihon Rinsho; 2007 Jun; 65 Suppl 6():559-62. PubMed ID: 17682211
[No Abstract] [Full Text] [Related]
10. Black cohosh (Cimicifuga racemosa) in tamoxifen-treated breast cancer patients with climacteric complaints - a prospective observational study.
Rostock M; Fischer J; Mumm A; Stammwitz U; Saller R; Bartsch HH
Gynecol Endocrinol; 2011 Oct; 27(10):844-8. PubMed ID: 21231853
[TBL] [Abstract][Full Text] [Related]
11. Undetectable antimüllerian hormone levels and recovery of chemotherapy-induced ovarian failure in women with breast cancer on an oral aromatase inhibitor.
Dieudonné AS; Vandenberghe J; Geerts I; Billen J; Paridaens R; Wildiers H; Neven P
Menopause; 2011 Jul; 18(7):821-4. PubMed ID: 21326118
[TBL] [Abstract][Full Text] [Related]
12. [Adjuvant endocrine therapy in breast cancer. Management of early-risk relapse].
Chahine G; Howayek M; Atallah D
J Med Liban; 2009; 57(2):124-9. PubMed ID: 19623889
[TBL] [Abstract][Full Text] [Related]
13. Aromatase inhibitors in breast cancer: an overview.
Altundag K; Ibrahim NK
Oncologist; 2006 Jun; 11(6):553-62. PubMed ID: 16794235
[TBL] [Abstract][Full Text] [Related]
14. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98.
Coates AS; Keshaviah A; Thürlimann B; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Colleoni M; Láng I; Del Mastro L; Smith I; Chirgwin J; Nogaret JM; Pienkowski T; Wardley A; Jakobsen EH; Price KN; Goldhirsch A
J Clin Oncol; 2007 Feb; 25(5):486-92. PubMed ID: 17200148
[TBL] [Abstract][Full Text] [Related]
15. [Adjuvant antihormonal therapy for postmenopausal women with primary operable breast cancer].
Tuxen MK; Nielsen DL; Lindberg H; Kamby C
Ugeskr Laeger; 2007 Jan; 169(4):297-9. PubMed ID: 17274922
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant endocrine treatment in primary breast cancer - review of literature.
Mathew J; Asgeirsson KS; Jackson LR; Cheung KL; Robertson JF
Breast; 2009 Dec; 18(6):339-44. PubMed ID: 19836953
[TBL] [Abstract][Full Text] [Related]
17. Identifying menopause in breast cancer patients: considerations and implications.
Clemons M; Simmons C
Breast Cancer Res Treat; 2007 Aug; 104(2):115-20. PubMed ID: 17061039
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant chemotherapy followed by goserelin compared with either modality alone: the impact on amenorrhea, hot flashes, and quality of life in premenopausal patients--the International Breast Cancer Study Group Trial VIII.
Bernhard J; Zahrieh D; Castiglione-Gertsch M; Hürny C; Gelber RD; Forbes JF; Murray E; Collins J; Aebi S; Thürlimann B; Price KN; Goldhirsch A; Coates AS;
J Clin Oncol; 2007 Jan; 25(3):263-70. PubMed ID: 17159194
[TBL] [Abstract][Full Text] [Related]
19. A practical overview of aromatase inhibitors in postmenopausal women with hormone receptor-positive breast cancer.
Younus J; Vandenberg TA
Bull Cancer; 2005 Apr; 92(4):E39-44. PubMed ID: 15888383
[TBL] [Abstract][Full Text] [Related]
20. Effectively nursing patients receiving aromatase inhibitor therapy.
Wengström Y
Breast; 2008 Jun; 17(3):227-38. PubMed ID: 18077168
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
